Pacira BioSciences (PCRX) 44th Annual J.P. Morgan Healthcare Conference summary

Business Overview and Strategic Vision

• Focused on innovative, non-opioid pain management, helping over 18 million patients and generating $726 million in unaudited 2025 sales with 800+ employees.

• Mission centers on delivering transformative pain therapies, guided by patient-centricity, scientific rigor, integrity, and team diversity.

• 5x30 strategy targets growth and value creation by 2030, focusing on musculoskeletal pain and adjacent markets.

• Portfolio includes EXPAREL (flagship nerve block), ZILRETTA (corticosteroid for osteoarthritis), and iovera (cryoneurolysis device).

• Achieved 40%+ stock price increase and highest historical margins, driven by manufacturing efficiency and robust commercial organization.

Strategic Initiatives, Partnerships, and Global Expansion

• Launched 5x30 strategy: help 3 million patients, double-digit top-line growth, five-point margin expansion, five new pipeline programs, and five partnerships by 2030.

• Signed key partnerships with Johnson & Johnson (tripling ZILRETTA reach) and LG Chem (Asia-Pacific commercial rights for EXPAREL and potential ZILRETTA sales), with regulatory filings planned for South Korea and Thailand in 2026.

• Acquired GQ Bio, securing the HCAd platform for PCRX-201 and initiated three preclinical programs (dry eye, degenerative disc disease, canine IL-1Ra).

• Five partnerships established, supporting global expansion and pipeline advancement.

• Settled with Fresenius and Hengrui, extending EXPAREL market visibility to 2039 and expanded IP estate to 21 patents.

Commercial Performance, Market Access, and Adoption

• NOPAIN legislation provides separate reimbursement for 11 products, including EXPAREL and iovera, at ASP plus 6 for Medicare outpatients.

• Covered lives reached 102 million in 2025, with early uptake in ambulatory surgery centers and smaller hospitals.

• Over 90% of EXPAREL business now contracted, supporting steady volume and top-line growth.

• Real-world evidence and HEOR data support expanded utilization and formulary wins.

• 82% of surveyed stakeholders view NOPAIN as important for non-opioid stewardship; 92% believe it reduces opioid prescribing.